Abstract

BackgroundEvidence is emerging that older women may tolerate breast cancer therapies equally well as the young ones, providing that they receive good supportive care. It has also been reported that these patients remain outside the current therapeutic standards. The aim of this observational study was to assess the access of breast cancer patients to medical procedures.MethodsWe retrospectively reviewed a database of breast cancer patients registered in the National Cancer Registry in Poland, searching for the numbers of new cases and deaths in the years 2010–2015. We obtained the numbers and costs of key medical procedures provided for these patients from the National Health Fund in Poland. Breast cancer survival in the years 2010–2015 was estimated based on the mortality/incidence ratio. The t-Student test and Spearman correlation coefficient were used for the analysis of data obtained from both databases.ResultsThere was no increase in survival throughout the years 2010–2015 in both analysed subpopulations of all breast cancer patients below and over 65 years of age, despite an unprecedented rise in healthcare funding in Poland. We noted 37% lower probability of 5-year survival in patients older than 65 years. The average number of outpatient visits and surgical procedures per person per year were slightly, yet significantly (p < 0.01), higher in younger vs. older patients (3.9 vs. 3.4 and 1.18 vs. 1.02, respectively). Outpatient chemotherapy was more common in older patients (6.0 vs. 5.25 cycles a year per person on average, p < 0.01). There were no significant differences in the average numbers of hospitalisations for chemotherapy, frequencies of radiotherapy and in the use of targeted therapy programmes (calculated per person per year), between younger and older patients.ConclusionsOlder women with breast cancer are treated similarly to younger patients, but have significantly worse chances to survive breast cancer in Poland. A simple increase in healthcare financing will not improve the survival in the elderly with breast cancer without developing funded individualised care and survivorship programmes.

Highlights

  • Evidence is emerging that older women may tolerate breast cancer therapies well as the young ones, providing that they receive good supportive care

  • Mortality/Incidence ratio (MIR) is a measure that was previously presented by others as associated with healthcare funding and this relationship corresponded in some cases to the outcomes of cancer patients [8, 16]

  • We have shown that the survival may not be strictly associated with the level of healthcare funding since there was no increase in survival at the end of the period of a clear rise in healthcare funding in Poland

Read more

Summary

Introduction

Evidence is emerging that older women may tolerate breast cancer therapies well as the young ones, providing that they receive good supportive care. It has been reported that these patients remain outside the current therapeutic standards. The aim of this observational study was to assess the access of breast cancer patients to medical procedures. It is supposed that suboptimal reimbursement costs may be the reason for non-compliance with guidelines [1]. As it has been shown elsewhere, the differences in healthcare systems between countries at different levels of socio-demographic development, and the socioeconomic status of patients within the healthcare system of a given country may influence breast cancer survival [2]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call